{'fraction_non_alphanumeric': 0.039634146341463415, 'fraction_numerical': 0.03353658536585366, 'mean_word_length': 4.663793103448276, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The determination of CA-50 antigen in women with cervical cancer.

Serum from 97 women with histologically proven squamous cell cervical carcinoma were analysed for the presence of tumour marker CA-50 using a commercially available assay (DELFIA). Although values ranged between 0.5–573.3 U/ml the majority of cases (75%) fell below 21.2 U/ml. There was no relationship between CA-50 antigen values and clinical stage of the disease as defined by FIGO, or prognosis. Furthermore the high false negative rate of this marker (51.5%) in patients with proven disease, and the lack of response following treatment, would preclude its use as a diagnostic screen.